US Stock MarketDetailed Quotes
RDHL Redhill Biopharma
- 5.573
- +0.067+1.22%
Close Jan 15 16:00 ET
7.10MMarket Cap-0.02P/E (TTM)
5.790High5.570Low10.01KVolume5.790Open5.506Pre Close56.68KTurnover0.83%Turnover Ratio0.06P/E (Static)1.27MShares31.50352wk High116.11P/B6.71MFloat Cap5.41052wk Low--Dividend TTM1.20MShs Float22220.000Historical High--Div YieldTTM4.00%Amplitude5.410Historical Low5.662Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Redhill Biopharma Stock Forum
Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass ...
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentTuesday, 10th December at 7:00 am
Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident
There are currently no known approved therapies for gas...
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
Monday, 2nd December at 7:00 am
RedHill has been awarded a judgment of approximately $8 millionplus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd
The Court dismissed the entirety of Kukbo's counterclaims, ruling in favor of RedHill's demonstrated good faith commitment to the spirit and the letter of the ag...
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVID-19, valid through 204
Published post-hoc data from opaganib's Phase2/3 study showed that patients with ≤60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) comp...
No comment yet